Buprenorphine for Opiate Analgesia in End-Stage Kidney Disease

Introduction to Buprenorphine in ESKD

Buprenorphine is the safest opioid of choice for patients with end-stage kidney disease (ESKD) and can be administered at normal doses without adjustment due to its predominantly hepatic metabolism, as recommended by the American Society of Nephrology 1, 2

Morphine, codeine, and meperidine should be avoided in ESKD patients due to accumulation of active metabolites, according to the Mayo Clinic Proceedings 3, 4
Tramadol and tapentadol are not recommended in renal insufficiency (GFR <30 mL/min/1.73 m²) and ESKD, as stated by the National Kidney Foundation 3

Hydrocodone, oxycodone, and hydromorphone should be used with caution and require dosage adjustment in ESKD patients, as recommended by the American College of Physicians 3

Buprenorphine (transdermal or other routes) is the safest choice with no dose adjustment needed, according to the European Renal Association 1, 2
Fentanyl (transdermal or intravenous) is safe but requires monitoring, as stated by the American Pain Society 5, 6
Methadone is safe in ESKD but should only be administered by clinicians experienced in its use due to risk of accumulation, according to the Centers for Disease Control and Prevention 3

Transdermal buprenorphine is particularly useful for patients with stable opioid requirements, as recommended by the American Society of Anesthesiologists 7
Transdermal formulations (buprenorphine, fentanyl) are best for patients who are unable to swallow, have poor tolerance to other opioids, or compliance issues, according to the European Society of Medical Oncology 2
Oral and intravenous formulations of buprenorphine are also available with high relative potency compared to oral morphine, as stated by the World Health Organization 1

For patients with ESKD requiring opioid analgesia, buprenorphine should be considered as first-line therapy, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2
Start with appropriate dosing based on the administration route (transdermal: 17.5-35 μg/h; oral: 0.4 mg; IV: 0.3-0.6 mg), according to the American Academy of Pain Medicine 1

While buprenorphine is a partial agonist, this characteristic actually contributes to its safety profile in ESKD patients, as stated by the American Society of Addiction Medicine 2